Compare SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SP Funds S&P 500 Sharia Industry Exclusions ETF vs TransMedics Group Inc — how do they compare? SP Funds S&P 500 Sharia Industry Exclusions ETF trades at $57.02, while TransMedics Group Inc trades at $74.3 (market cap $2.54B). The key difference: SP Funds S&P 500 Sharia Industry Exclusions ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| SPUS | TMDX | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $59.51 | $150.42 |
52-Week Low | $45.32 | $61.99 |
Market Cap | — | $2.54B |
Enterprise Value | — | $2.94B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SP Funds S&P 500 Sharia Industry Exclusions ETF
SPUS tracks a market-cap weighted index of S&P 500 stocks that adhere to Sharia law. It screens out companies involved in non-compliant business activities such as alcohol, tobacco, gambling, and conventional finance, as well as excluding sectors like Aerospace & Defense, and Data Processing. By focusing on low-leverage stocks, SPUS provides investors with a value-conscious, ethically-aligned exposure to a diversified portfolio of large-cap U.S. equities.
Read more on SPUS →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
